Philippines

Reimbursed Care Access

The Philippines maintains a restrictive national drug regime under Republic Act No. 9165 (the Comprehensive Dangerous Drugs Act) and implementing Board regulations. Most classical psychedelics (psilocybin, MDMA, DMT/5‑MeO‑DMT, mescaline, ibogaine, ayahuasca, 2C‑series) are treated as prohibited/controlled substances with no authorized medical uses outside approved research; ketamine is explicitly listed as a dangerous drug but permitted for licensed medical use under DDB regulation and is routinely used in hospitals (as an anesthetic or off‑label psychiatric intervention), while esketamine (Spravato) has no public record of national registration/coverage in the Philippines market at the time of this report. Citations to the governing law and DDB rulings are provided in compound entries below. [https://lawphil.net/statutes/repacts/ra2002/ra_9165_2002.html|RA 9165] [https://elibrary.judiciary.gov.ph/thebookshelf/showdocs/11/47967|DDB Board Regulation No. 3].